Powder: -20°C for 3 years | In solvent: -80°C for 1 year
XL177A 是一种选择性不可逆的 USP7 抑制剂,IC50为 0.34 nM。它通过 p53 依赖性机制引发癌杀伤细胞作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 797 | 现货 | ||
5 mg | ¥ 1,990 | 现货 | ||
10 mg | ¥ 3,160 | 现货 | ||
25 mg | ¥ 5,220 | 现货 | ||
50 mg | ¥ 7,370 | 现货 | ||
100 mg | ¥ 9,930 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,990 | 现货 |
产品描述 | XL177A is a selective irreversible USP7 inhibitor(IC50 : 0.34 nM). XL177A elicits cancer cell killing through a p53-dependent mechanism. |
靶点活性 | USP7:0.34 nM |
体外活性 | XL177A irreversibly inhibits USP7 with sub-nM potency and selectivity across the human proteome.?Evaluation of the cellular effects of XL177A reveals that selective USP7 inhibition suppresses cancer cell growth predominantly through a p53-dependent mechanism:?XL177A specifically upregulates p53 transcriptional targets transcriptome-wide, hotspot mutations in TP53 but not any other genes predict response to XL177A across a panel of ~500 cancer cell lines, and TP53 knockout rescues XL177A-mediated growth suppression of TP53 wild-type (WT) cells.?Together, these findings suggest TP53 mutational status as a biomarker for response to USP7 inhibition.?We find that Ewing sarcoma and malignant rhabdoid tumor (MRT), two pediatric cancers that are sensitive to other p53-dependent cytotoxic drugs, also display increased sensitivity to XL177A. |
分子量 | 861.47 |
分子式 | C48H57ClN8O5 |
CAS No. | 2417089-74-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/ml (63.84 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.1608 mL | 5.804 mL | 11.6081 mL | 29.0202 mL |
5 mM | 0.2322 mL | 1.1608 mL | 2.3216 mL | 5.804 mL | |
10 mM | 0.1161 mL | 0.5804 mL | 1.1608 mL | 2.902 mL | |
20 mM | 0.058 mL | 0.2902 mL | 0.5804 mL | 1.451 mL | |
50 mM | 0.0232 mL | 0.1161 mL | 0.2322 mL | 0.5804 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
XL177A 2417089-74-6 Cell Cycle/Checkpoint DNA Damage/DNA Repair Ubiquitination DUB MCF7 Deubiquitinase inhibit Inhibitor cancer XL-177A DUBs p53 USP7 inhibitor